|
Primary Ciliary Dyskinesia
|
0.310 |
Biomarker
|
disease |
BEFREE |
This is the first study to implicate CCNO, a DNA repair gene reported to be involved in multiciliogenesis, in PCD.
|
24824133 |
2015 |
|
Hydrocephalus
|
0.120 |
GeneticVariation
|
disease |
BEFREE |
Our results further establish <i>CCNO</i> as an important gene for normal development and suggest that heterozygous CCNO mutations could underlie hydrocephalus or diminished fertility in some human patients.
|
29245899 |
2017 |
|
Hydrocephalus
|
0.120 |
Biomarker
|
disease |
BEFREE |
Combining these 15 patients with the previously reported CCNO case reports revealed rapid deterioration in lung function, an increased prevalence of hydrocephalus (10%) as well as increased female infertility (22%).
|
26777464 |
2016 |
|
Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Further independent validation of our microRNA profile in RNA-seq data from patients treated with bevacizumab (alone or in combination with CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our microRNA profile predicted patient benefit from bevacizumab (HR = 0.59, p = 0.043).
|
27396951 |
2016 |
|
Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM).
|
26762204 |
2016 |
|
Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O<sup>6</sup>-methylguanine-DNA-methyltransferase (MGMT) promoter methylation.
|
29892208 |
2018 |
|
Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
We retrospectively identified and analyzed the characteristics of patients with glioblastoma rechallenged with a bevacizumab-based chemotherapy regimen after having received bevacizumab as first-line treatment in association with temozolomide radiochemotherapy or at recurrence in association with temozolomide, CCNU or irinotecan.Twenty-five patients were identified.
|
29388033 |
2018 |
|
Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
We evaluated the immunohistochemical MGMT expression in 28 consecutive oligodendroglial tumors (21 oligodendrogliomas, 5 mixed oligoastrocytomas, and 2 glioblastomas with prominent oligodendroglial features; 13 treated with CCNU) and compared it with that of 13 glioblastomas.
|
16038527 |
2005 |
|
Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The methods combined three steps before were used to screen core genes that influenced Me-CCNU chemosensitivity in GBM.
|
21807073 |
2011 |
|
Glioblastoma Multiforme
|
0.060 |
Biomarker
|
disease |
BEFREE |
Further independent validation of our microRNA profile in RNA-seq data from patients treated with bevacizumab (alone or in combination with CCNU) at glioblastoma recurrence in the BELOB trial confirmed that our microRNA profile predicted patient benefit from bevacizumab (HR = 0.59, p = 0.043).
|
27396951 |
2016 |
|
Glioblastoma Multiforme
|
0.060 |
Biomarker
|
disease |
BEFREE |
The methods combined three steps before were used to screen core genes that influenced Me-CCNU chemosensitivity in GBM.
|
21807073 |
2011 |
|
Glioblastoma Multiforme
|
0.060 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to evaluate the feasibility of procarbazine and CCNU chemotherapy for recurrent glioblastoma multiforme (GBM) with O<sup>6</sup>-methylguanine-DNA-methyltransferase (MGMT) promoter methylation.
|
29892208 |
2018 |
|
Glioblastoma Multiforme
|
0.060 |
Biomarker
|
disease |
BEFREE |
The results from the randomized phase II BELOB trial provided evidence for a potential benefit of bevacizumab (beva), a humanized monoclonal antibody against circulating VEGF-A, when added to CCNU chemotherapy in patients with recurrent glioblastoma (GBM).
|
26762204 |
2016 |
|
Glioblastoma Multiforme
|
0.060 |
Biomarker
|
disease |
BEFREE |
Consequently, CCNU might be preferentially considered as a treatment option for recurrent MGMT-methylated GBM and may even be suitable for prevention of resistance evolution in primary treatment.
|
28825189 |
2018 |
|
Glioblastoma Multiforme
|
0.060 |
Biomarker
|
disease |
BEFREE |
We retrospectively identified and analyzed the characteristics of patients with glioblastoma rechallenged with a bevacizumab-based chemotherapy regimen after having received bevacizumab as first-line treatment in association with temozolomide radiochemotherapy or at recurrence in association with temozolomide, CCNU or irinotecan.Twenty-five patients were identified.
|
29388033 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We evaluated the prognostic and predictive value of a range of molecular changes in the setting of a randomised trial comparing standard PCV (procarbazine, CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea) and vincristine) chemotherapy with the standard temozolomide (TMZ) 5-day (200 mg/m2/day) schedule and a 21-day (100 mg/m2/day) schedule in chemo-naïve, high-grade glioma (non-oligodendroglial tumours; WHO (World Health Organisation) grades III and IV) patients at first progression following radiotherapy.354 samples (79.2%) from the first operation of the 447 randomised patients provided enough tumour DNA for some or all parts of the study.
|
24952577 |
2014 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Data from 368 patients with AOD or AOA recruited in The European Organisation for Research and Treatment of Cancer (EORTC) trial 26951 on adjuvant PCV (Procarbazine, CCNU, Vincristine) chemotherapy in anaplastic oligodendroglial tumours were used to develop multifactor models to predict progression free survival (PFS) and overall survival (OS).
|
23896377 |
2013 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
For example, co-deletion of chromosome arms 1p and 19q predicts benefit from polychemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) in patients with anaplastic oligodendroglioma, and the presence of 1p/19q co-deletion was integrated as a defining feature of oligodendroglial tumors in the revised WHO classification.
|
27501915 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
After a maximal safe resection, postoperative craniospinal irradiation for a total dose of 36 Gy plus a sequential boost to the tumor bed to 54 Gy, and adjuvant chemotherapy with CDDP plus CCNU plus vincristine were performed.
|
31092461 |
2019 |
|
Anaplastic Oligodendroglioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The long-term follow-up results from the EORTC-26951 trial showed that the addition of procarbazine, CCNU, and vincristine (PCV) after radiotherapy increases survival in anaplastic oligodendrogliomas/oligoastrocytomas (AOD/AOA).
|
23948976 |
2013 |
|
Anaplastic Oligodendroglioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
For example, co-deletion of chromosome arms 1p and 19q predicts benefit from polychemotherapy with procarbazine, CCNU (lomustine), and vincristine (PCV) in patients with anaplastic oligodendroglioma, and the presence of 1p/19q co-deletion was integrated as a defining feature of oligodendroglial tumors in the revised WHO classification.
|
27501915 |
2016 |
|
Anaplastic Oligodendroglioma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Data from 368 patients with AOD or AOA recruited in The European Organisation for Research and Treatment of Cancer (EORTC) trial 26951 on adjuvant PCV (Procarbazine, CCNU, Vincristine) chemotherapy in anaplastic oligodendroglial tumours were used to develop multifactor models to predict progression free survival (PFS) and overall survival (OS).
|
23896377 |
2013 |
|
Lung diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
In PCD, there was significant heterogeneity of lung disease, patients who had pathogenic variants in CCNO presented earlier, and those with CCDC40 and CCNO had worse lung disease, and poorer nutritional status compared with the other subgroups.
|
31765523 |
2020 |
|
Lung diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Using a whole-exome sequencing strategy, we identified recessive CCNO (encoding cyclin O) mutations in 16 individuals suffering from chronic destructive lung disease due to insufficient airway clearance.
|
24747639 |
2014 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We retrospectively identified and analyzed the characteristics of patients with glioblastoma rechallenged with a bevacizumab-based chemotherapy regimen after having received bevacizumab as first-line treatment in association with temozolomide radiochemotherapy or at recurrence in association with temozolomide, CCNU or irinotecan.Twenty-five patients were identified.
|
29388033 |
2018 |